Figshareopen access

Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China

Name: Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China
License: Open Access

Weiqi Chen (1806721) et al.

Figshare · Datasets · License: Open Access

Open Source ↗

biotechnology cancer pharmacology science-policy

medicine, pharmacology, biotechnology, cancer, science policy, biological sciences not elsewhere classified, zanubrutinib, ibrutinib

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 684722
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.